Last Patient in Isotechnika's Kidney Transplant Trial Completes Treatment
Posted on: Friday, 4 January 2008, 09:00 CST
Biopharmaceutical company Isotechnika has announced that the last patient enrolled in the company's Phase IIb kidney transplant trial has completed the six-month trial.
Patients who have completed the six months trial were provided the opportunity to continue treatment with ISA247 as part of an extension to the initial trial. This six-month extension period will provide longer-term safety and efficacy data for the drug in de novo kidney transplant patients.
Previously, Isotechnika has received permission from Health Canada and the FDA to allow patients to remain on ISA247 until the drug is commercially available.
Robert Foster, Isotechnika's chairman and CEO, said: "The six-month data is expected to be available in the second quarter of this year. We believe that the final data will confirm ISA247 as an efficacious treatment for kidney transplant patients with an enhanced safety profile over current calcineurin inhibition therapies. Efficacy and enhanced safety profile will be key characteristics of the next generation of calcineurin inhibitors and ensure that calcineurin inhibition remains the foundation of evidence-based medicine."
Source: Datamonitor
Related Articles
- Pervasis Therapeutics to Present Safety and Efficacy Data From Phase 1 and 2 Clinical Trials of Vascugel(R) at the 35th Annual VEITHsymposium(TM)
- 338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
- MicroIslet Provides Safety and Efficacy Data Update
- Symantec Joins the U.S. Senate in Reaching Out to Educate Families During National Internet Safety Month
- Thallion Announces Positive Safety and Efficacy Data From ECO-4601 Phase I/II Trial
- Auto Dealers to Promote Child Passenger Safety Month in September
- Net Nanny (From ContentWatch) Supports Internet Safety Month With Top Ten Internet Safety Tips, June Price Discount
- US Senate Declares June ``Internet Safety Month''; Bsafe Online Does Its Part Year-Round
- Genmab A/S and Medarex Announce Positive Safety and Efficacy Data in Phase I/II Trial With HuMax-Inflam/MDX-018
 |
 |
User Comments (0)
RSS Feeds